Terumo Set To Build On Long-Term VAD Investments With Upcoming Trials
This article was originally published in PharmAsia News
Executive Summary
Terumo Corporation's long journey toward comercialization of the DuraHeart ventricular assist device is about to take a major step forward with the start of a U.S. "bridge-to-transplant" trial and the upcoming launch of a "destination therapy" trial
You may also be interested in...
Thoratec Sends HeartWare Early Valentine: $282 Million Proposal Is Accepted
Thoratec will expand its presence in the heart failure market through its $282 million acquisition of miniaturized ventricular assist device maker HeartWare
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).